1. Home
  2. YHGJ vs IMRN Comparison

YHGJ vs IMRN Comparison

Compare YHGJ & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunhong Green CTI Ltd.

YHGJ

Yunhong Green CTI Ltd.

HOLD

Current Price

$2.78

Market Cap

7.2M

Sector

Industrials

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.82

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YHGJ
IMRN
Founded
1975
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2M
6.2M
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
YHGJ
IMRN
Price
$2.78
$0.82
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.6K
19.1K
Earning Date
05-19-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,705,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.76
N/A
52 Week Low
$0.47
$0.68
52 Week High
$10.29
$2.38

Technical Indicators

Market Signals
Indicator
YHGJ
IMRN
Relative Strength Index (RSI) 47.36 52.49
Support Level $2.52 $0.69
Resistance Level $3.03 $0.89
Average True Range (ATR) 0.22 0.06
MACD 0.01 0.01
Stochastic Oscillator 28.35 53.87

Price Performance

Historical Comparison
YHGJ
IMRN

About YHGJ Yunhong Green CTI Ltd.

Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: